20

25

30

CLAIMS

1. DNA comprising one or more genes specific for 5S clavam biosynthesis in S. clavaligerus and which is not essential for 5R clavam biosynthesis.

DNA according to claim 1 as identified in Figure 1 (SEO ID No: 1).

- DNA according to claim 1 having the sequence or substantially the sequence shown in Figure 1 as orfup3, orfup2, orfup1, orfdwn 1, orfdwn2 or orfdwn3 (SEQ ID Nos: 2-7).
- DNA according to claim 1 having the sequence or substantially the sequence shown in Figure 1 as orfup1 (SEQ ID No: 4).
- DNA which hybridises under conditions of high stringency with the DNA of claim 1.
 - A vector comprising the DNA of claim 1 in which one or more of the genes specific for 5S clavam biosynthesis has been disrupted or otherwise made defective.
 - A vector according to claim 6 containing one or more defective genes which is pCEC060, pCEC061, pCEC056 or pCEC057.
 - A vector according to claim 7 which is pCEC061.
 - 9. A host containing the vector of claim 6.
 - A host according to claim 9 which is capable of producing raised levels of clavulanic acid.
 - A host according to claim 9 which is capable of producing low or no levels of 5S clavam.

- 12. A host according to claim 9 which is S. clavuligerus.
- S. clavuligerus comprising DNA corresponding to an open reading frame
 flanking cas1 which DNA has been disrupted or otherwise made defective.
 - 14. S. clavuligerus according to claim 13 wherein the open reading frame is selected from the group consisting of orfup3, orfup2, orfup1, orfdwn1, orfdwn2 and orfdwn3

- 15. A process for improving 5R clavam production in a suitable microorganism comprising manipulation of DNA as defined in claim 1 and its inclusion in the microorganism.
- 15 16. A process according to claim 15 wherein said suitable microorganism is S. clavuligerus.
 - 17. A process for improving 5R clavam production in S. clavaligerus comprising disrupting or otherwise making defective DNA regions flanking cas1.

20

- 18. A process according to claim 15 wherein said DNA corresponds to open reading frames selected from the group consisting of orfup3, orfup2, orfup1, orfdwn 1, orfdwn2 and orfdwn3.
- 25 19. A process according to claim 15 wherein said DNA corresponds to open reading frame orfup1.
 - 20. A process according to claim 15 wherein said 5R clavam is clavulanic acid.
- 30 21. A process for the identification of a microorganism suitable for high 5R clavam production comprising a preliminary screening for microorganisms with low or no 5S clavam production.

- 22. A process according to claim 21 wherein the microorganism is S. clavuligerus.
- 23. A process according to claim 22 wherein the 5R clavam is clavulanic acid.

10

20

- 24. A process according to claim 21 wherein one or more genes specific for the production of 5S clavams is defective.
- A microorganism which is capable of 5R clavam production and low or no 5S clavam production obtainable by the process of claim 15.
 - A microorganism obtainable by the process of claim 25 which is capable of producing clavulanic acid but which does not produce clavam-2- carboxylate.
- 15 27. A microorganism obtainable by the process of claim 25 which is capable of producing clavulanic acid but which does not produce 2-hydroxymethylclavam.
 - 28. A microorganism obtainable by the process of claim 25 which is capable of producing clavulanic acid but which does not produce clavam-2- carboxylate and 2hydroxymethylclavam.
 - A microorganism obtained by the process of claim 15 which is strain 56-1A,
 56-3A, 57-2B, 57-1C, 60-1A, 60-2A, 60-3A, 61-1A, 61-2A, 61-3A or 61-4A.
- 25 30. Clavulanic acid obtainable by the fermentation of a microrganism as defined in claim 25
 - 31. Clavulanic acid according to claim 30 which is free of clavam-2-carboxylate.
- 30 32. Clavulanic acid according to claim 30 in the form of its potassium salt.
 - Clavulanic acid which is free of any 5S clavam.

- 34. Clavulanic acid which is free of any clavam-2-carboxylate.
- A composition comprising potassium clavulanate according to claim 32 in combination with a beta-lactam antibiotic.
 - A composition according to claim 35 in which the beta-lactam antiobiotic is amoxycillin.
- 10 37. A process for the preparation of a composition comprising potassium clavulanate and amoxycillin which process comprises producing clavulanic acid from a microorganism according to claim 25 and thereafter converting it to the potassium salt and combining the potassium salt with amoxycillin.